Earnings summaries and quarterly performance for Viatris.
Executive leadership at Viatris.
Board of directors at Viatris.
David Simmons
Detailed
Director
Elisha Finney
Detailed
Director
Frank D’Amelio
Detailed
Director
Harry Korman
Detailed
Director
James M. Kilts
Detailed
Director
JoEllen Lyons Dillon
Detailed
Director
Leo Groothuis
Detailed
Director
Mark Parrish
Detailed
Vice Chair of the Board
Melina Higgins
Detailed
Chair of the Board
Michael Severino
Detailed
Director
Rajiv Malik
Detailed
Director
Richard Mark
Detailed
Director
Rogério Vivaldi Coelho
Detailed
Director
W. Don Cornwell
Detailed
Director
Research analysts who have asked questions during Viatris earnings calls.
David Amsellem
Piper Sandler Companies
6 questions for VTRS
Also covers: ABBV, ALKS, AMGN +27 more
Ashwani Verma
UBS Group AG
5 questions for VTRS
Also covers: ACAD, ALKS, ALVO +12 more
Christopher Schott
JPMorgan Chase & Co.
5 questions for VTRS
Also covers: ABBV, AMGN, AMRX +15 more
Jason Gerberry
Bank of America Merrill Lynch
4 questions for VTRS
Also covers: ALKS, AMPH, ARWR +21 more
Umer Raffat
Evercore ISI
4 questions for VTRS
Also covers: ALKS, AMGN, BHC +15 more
Matt Dellatorre
Goldman Sachs
3 questions for VTRS
Balaji Prasad
Barclays
2 questions for VTRS
Also covers: ALVO, AMRX, ELAN +7 more
Jason Gerbery
Bank of America
2 questions for VTRS
Also covers: IONS
Leszek Sulewski
Truist Securities
2 questions for VTRS
Also covers: AKBA, AMRX, ANIP +6 more
Ash Verma
UBS
1 question for VTRS
Also covers: ALVO, AVDL, EXEL +5 more
JP
Evercore ISI
1 question for VTRS
Li Wenwen
Danasting
1 question for VTRS
Recent press releases and 8-K filings for VTRS.
Viatris provides pipeline update on four regulatory milestones
VTRS
Product Launch
New Projects/Investments
- FDA approval of generic octreotide acetate LAR depot injectable suspension for acromegaly and carcinoid tumour indications
- FDA acceptance of NDA for a once-weekly low-dose estrogen patch (150 mcg norelgestromin/17.5 mcg ethinyl estradiol) with a PDUFA target date of July 30, 2026
- FDA clearance of IND for MR-146 AAV gene therapy in neurotrophic keratopathy, with a Phase 1/2 CORVITA trial planned in H1 2026
- PMDA acceptance of J-NDA for pitolisant in obstructive sleep apnea syndrome; narcolepsy J-NDA submission expected by year-end 2025
2 days ago
Viatris announces monetization of Biocon Biologics stake
VTRS
M&A
- Viatris will sell its convertible preferred equity in Biocon Biologics for $815 million total consideration: $400 million in cash and $415 million in newly issued Biocon Limited shares.
- The agreement accelerates biosimilars non-compete restrictions, which will lapse immediately for ex-U.S. markets and in November 2026 for U.S. markets.
- The transaction is expected to close in Q1 2026, subject to customary closing conditions.
- Citi is acting as financial advisor, with Cravath, Swaine & Moore LLP and Khaitan & Co. as legal advisors to Viatris.
Dec 8, 2025, 12:00 PM
Viatris to monetize Biocon Biologics stake
VTRS
M&A
Convertible Preferred Issuance
- Viatris enters agreements to sell its convertible preferred equity stake in Biocon Biologics for $815 million total consideration ($400 million cash + $415 million Biocon shares).
- Shares are subject to a six-month lock-up and will trade on the National Stock Exchange of India.
- The deal accelerates expiration of biosimilars non-compete restrictions, effective at close outside the U.S. and in November 2026 for U.S. markets.
- The transaction is expected to close in Q1 2026, pending satisfaction of closing conditions.
Dec 6, 2025, 2:00 PM
Viatris outlines strategic review and growth plan at Evercore HealthCONx Conference
VTRS
Guidance Update
New Projects/Investments
- Viatris is executing an enterprise-wide strategic review to optimize cost structure and position for sustained revenue and earnings growth beyond 2026.
- The company expects its base business to generate approximately $200 million of net annual growth, supplemented by innovative assets from its pipeline and M&A activity.
- Over a three-year period, Viatris aims to capture significant, sticky cost savings—after allowing for reinvestment—with the majority flowing through to the bottom line.
- It plans to deploy about $2 billion in annual free cash flow equally between shareholder returns (dividends and buybacks) and building its growth pipeline.
- Key pipeline highlights include fast-acting meloxicam for acute pain with an opioid-sparing claim expected, and on-demand antiplatelet selatogrel for acute MI, both in late-stage development and targeted for launch in late 2026.
Dec 3, 2025, 1:45 PM
Viatris outlines strategic review and growth drivers at HealthCONx Conference
VTRS
Guidance Update
New Projects/Investments
- Viatris is organized into a global generics business, an established products segment (e.g., Lipitor, Norvasc), and an innovative pipeline, with five of six Phase 3 readouts positive in 2025.
- Returned over $1 billion to shareholders in 2025 via dividends and share repurchases; plans to allocate ~50% of $2 billion annual free cash flow to returns over the next 3–5 years.
- Initiated an enterprise-wide strategic review to realize multiyear cost savings, reinvest in new product launches, and drive sustained revenue and earnings growth from 2026 onward.
- Acquired Aculys-Japan assets (Pitolisant and Speedia) to leverage existing CNS infrastructure and reverse revenue declines in the Japanese market.
- Key upcoming catalysts include the PDUFA submission for fast-acting meloxicam (launch toward end of 2026), and Phase 3 readouts for selatogrel and cenerimod in late 2026.
Dec 3, 2025, 1:45 PM
Viatris outlines strategy for sustained revenue and earnings growth
VTRS
- Viatris is organized into three separate businesses—global generics, established Upjohn brands, and a growing innovative segment—and has launched an enterprise-wide strategic review to position for sustained revenue and earnings growth from 2026 onward.
- The base generics and established products business is expected to generate approximately $500 million in new annual revenues, absorb $300 million in losses and price declines, and still yield a net $200 million of sustainable yearly growth.
- An ongoing three-year cost-reduction program aims to deliver significant, sticky savings, with the majority flowing to the bottom line after partial reinvestment in new product launches.
- Viatris generates about $2 billion of free cash flow annually, deploying it roughly 50/50 between shareholder returns (dividends and buybacks) and investing in its pipeline and in-market acquisitions.
- Key pipeline catalysts include a late-2026 launch of fast-acting meloxicam with a 45-minute onset and opioid-sparing claim , the self-administered selatogrel Phase 3 program for acute MI , and two Phase 3 trials of cenerimod in lupus.
Dec 3, 2025, 1:45 PM
Versanis details capital strategy and pipeline updates at Piper Sandler Healthcare Conference
VTRS
- Versanis aims for a 50/50 split over 3–5 years between capital deployment (business development) and capital return, leaning into share buybacks this year amid favorable stock performance.
- Cenerimod’s Phase III SLE program (OPUS-2 fully enrolled) and a parallel lupus nephritis Phase III program are advancing on plan, targeting oral once-daily add-on therapy data in 2026.
- Selatogrel Phase III enrollment has accelerated to ~1,000 patients/month, with full enrollment expected by year-end and top-line results anticipated in late 2026/early 2027.
- A pre-NDA meeting for fast-acting meloxicam is scheduled, with potential for an accelerated review; commercialization will focus on outpatient and in-office acute pain settings.
- An enterprise-wide strategic review of commercial, R&D, manufacturing, and corporate functions is underway to deliver multi-year net savings and fund growth, with results due early 2026.
Dec 2, 2025, 1:30 PM
Viatris outlines capital strategy, pipeline progress, and cost review
VTRS
Share Buyback
Product Launch
- Viatris targets a 50/50 split over a 3–5-year horizon between capital return (notably share buybacks this year) and business development, with a focus on U.S. branded, higher-margin assets.
- Cenerimod’s Phase III SLE trials (OPUS-2 fully enrolled; OPUS-1 starting soon) and new Phase III lupus nephritis program leverage its oral, once-daily profile and demonstrated PK in renal impairment.
- Selatogrel’s global Phase III acute MI study is enrolling ~1,000 patients/month, on track for full enrollment by year-end, with top-line results expected late 2026/early 2027; rival zalunfiban data bolster its 21% risk-reduction goal.
- Fast-acting meloxicam (505(b)(2)) is gearing up for an NDA pre-meeting with FDA imminently, aiming for accelerated review, targeting outpatient and office-based acute pain, and at least 3 years exclusivity plus pending patent extensions.
- An enterprise-wide strategic review across commercial, R&D, manufacturing, and corporate functions seeks multi-year net savings to reinvest in sustainable revenue and EBITDA growth, with outcomes due early next year.
Dec 2, 2025, 1:30 PM
Viatris outlines balanced capital allocation and advances pipeline at Piper Sandler Healthcare Conference
VTRS
Share Buyback
M&A
- Maintains a 50/50 capital allocation between deployment and shareholder returns, prioritizing share buybacks this year given operational context.
- Pursuing commercial-stage branded, patent-protected assets, highlighted by the Aculys Pharma transaction adding Pitolisant and Sunosi in Japan.
- Cenerimod: two Phase III SLE trials (OPUS-2 fully enrolled, OPUS-1 upcoming) and new Phase III lupus nephritis program; Selatogrel Phase III acute MI trial nearing full enrollment with top-line data expected late 2026/early 2027.
- Pre-NDA meeting planned for fast-acting meloxicam, focusing on outpatient and in-office acute pain, with at least 3 years exclusivity under 505(b)(2) and potential extensions.
- An enterprise-wide strategic review is ongoing to identify multi-year net savings across commercial, R&D, manufacturing, and support functions, with results due early next year.
Dec 2, 2025, 1:30 PM
Viatris outlines 2025 progress, strategic review and 2026 outlook at Jefferies Conference
VTRS
Share Buyback
Dividends
Guidance Update
- 2025 performance: Viatris delivered five positive Phase III readouts out of six and achieved strong commercial execution across geographies; returned ~$500 million in share buybacks year-to-date and expects to exceed $1 billion in total capital returns (dividends + buybacks) during 2025.
- Enterprise-wide strategic review: Five years post-merger, management is conducting a deep cost and organizational assessment across sales, R&D, manufacturing and support functions, targeting meaningful savings (majority to bottom line, with a portion reinvested).
- Manufacturing facility update: Indoor plant remediation is > 90% complete; FDA will conduct a surprise reinspection—likely in H1 2026—with the goal of a non-event from a financial and supply-chain perspective.
- Pipeline & 2026 guidance: The company expects $450 million–$550 million in new product revenue in 2026 from complex generics (e.g., octreotide) excluding fast-acting meloxicam and Xulane ; fast-acting meloxicam NDA to be filed by year-end for 2026 launch, differentiated by a 45-minute T_max and opioid-sparing effect.
- Balanced capital allocation: Strategy emphasizes a mix of dividends, share buybacks and business development for in-market, accretive assets, leveraging Viatris’s 165-country footprint (notably recent Japanese acquisitions).
Nov 18, 2025, 11:30 AM
Quarterly earnings call transcripts for Viatris.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more